| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q2 2012 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 43 | Q2 2024 | 5.1% |
| BIOMARIN PHARMACEUTICAL INC | 43 | Q2 2024 | 5.0% |
| ALKERMES PLC | 43 | Q2 2024 | 3.3% |
| LILLY ELI & CO | 42 | Q2 2024 | 5.8% |
| INTRA-CELLULAR THERAPIES INC | 42 | Q2 2024 | 2.4% |
| VERTEX PHARMACEUTICALS INC | 41 | Q2 2024 | 4.3% |
| REVANCE THERAPEUTICS INC | 41 | Q2 2024 | 0.9% |
| ABBVIE INC | 40 | Q2 2024 | 4.4% |
| CVS HEALTH CORP | 40 | Q4 2023 | 3.5% |
| JAZZ PHARMACEUTICALS PLC | 40 | Q2 2024 | 3.1% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-13 |
| 13F-HR | 2024-08-13 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.